Oxford Biomedica plc (LON:OXB - Get Free Report) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 368.76 ($4.92) and traded as low as GBX 291 ($3.89). Oxford Biomedica shares last traded at GBX 300 ($4.01), with a volume of 243,373 shares trading hands.
Oxford Biomedica Trading Down 3.1 %
The stock has a market cap of £309.04 million, a price-to-earnings ratio of -2.16 and a beta of 1.09. The business has a 50-day simple moving average of GBX 290.59 and a two-hundred day simple moving average of GBX 368.76. The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35.
Oxford Biomedica (LON:OXB - Get Free Report) last announced its earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.56)) EPS for the quarter. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%. As a group, research analysts forecast that Oxford Biomedica plc will post -31.0799998 EPS for the current year.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
